Understand the source comparison
ARA-290 vs EPO vs Standard Neuropathy Treatments: Mechanism Comparison
ARA-290 (4–8mg daily) Selective βCR-EPOR activation → JAK2-STAT3 anti-inflammatory signaling Yes. IENFD increase of 78% at 28 days (Leiden trial) None. No red blood cell production Phase 2 RCT in diabetic neuropathy (n=36, published Molecular Medicine 2015) Be
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290 (4–8mg daily)
- Selective βCR-EPOR activation → JAK2-STAT3 anti-inflammatory signaling
- Yes. IENFD increase of 78% at 28 days (Leiden trial)
- None. No red blood cell production
- Phase 2 RCT in diabetic neuropathy (n=36, published Molecular Medicine 2015)
- Best evidence for structural nerve repair; requires daily subcutaneous dosing for 28 days
- Erythropoietin (EPO)
- Full EPOR activation → JAK2-STAT5 erythropoiesis + JAK2-STAT3 neuroprotection
- Mixed. Neuroprotective but carries thrombotic risk
- High. Increases RBC count, hemoglobin, thrombotic events
- FDA black-box warnings; limited neuropathy trials due to safety concerns
- Effective but unsafe for neuropathy indication due to cardiovascular risks
- Gabapentin / Pregabalin
- Voltage-gated calcium channel blockade → reduced neurotransmitter release
- No. Symptom masking only, no fiber regrowth
- None
- Multiple RCTs for neuropathic pain; no effect on IENFD
- Standard of care for pain control; does not address nerve degeneration
- Alpha-Lipoic Acid (600mg daily)
- Antioxidant. Reduces oxidative stress in nerve tissue
- Modest. Small IENFD increases in some trials (0.5–1.0 fibers/mm)
- Meta-analysis of 4 RCTs showed NPS reduction of 2.8 points vs 1.4 placebo
- Adjunctive therapy; effect size much smaller than ARA-290
- NSAIDs / Acetaminophen
- COX inhibition → prostaglandin reduction
- No. Analgesic only, no regeneration
- Extensive pain evidence; zero neuropathy-specific trials
- Ineffective for neuropathic pain; works for nociceptive pain only